Quality of Life Validation in Laryngitis

Study identifier:294

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Laryngopharyngeal Reflux Health related Quality of Life (LPR-HRQL) Questionnaire Development and Psychometric testing in Patients Receiving Omeprazole 20 mg bid as Treatment for Laryngopharyngeal Reflux.

Medical condition

Laryngopharyngeal reflux (LPR)

Phase

Phase 4

Healthy volunteers

Study drug

Omeprazole

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 70 Years

Date

Study Start Date: 01 May 2001

Primary Completion Date: 01 Jun 2003

Study Completion Date: 01 Jun 2003

Study design

Allocation: N/A
Endpoint Classification: N/A
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic

Verification:

Verified 01 Jun 2009 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

Trial Results Summaries
Available here

Contacts

Contact

null AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Paula Fernstrom

Nexium Global Product Director, AstraZeneca